Nastech Pharmaceutical has started a Phase II trial of PYY3-36 nasal spray in obese patients. The study will enroll approximately 500 patients for a six-month, randomized, placebo-controlled, dose-ranging study with weight loss as the primary endpoint.
The study will evaluate three different doses of the spray versus placebo and Meridia (sibutramine), a commercially available oral weight loss drug. Patients will take the spray or placebo three times daily prior to a meal over the 24-week period.
The study also will evaluate other effects including the proportion of patients who lose at least 5 percent or 10 percent of their baseline body weight as well as the effect on hemoglobin A1c levels, Nastech said.
The study will evaluate three different doses of the spray versus placebo and Meridia (sibutramine), a commercially available oral weight loss drug. Patients will take the spray or placebo three times daily prior to a meal over the 24-week period.
The study also will evaluate other effects including the proportion of patients who lose at least 5 percent or 10 percent of their baseline body weight as well as the effect on hemoglobin A1c levels, Nastech said.